JP2006516140A - 有糸分裂キネシン阻害剤 - Google Patents

有糸分裂キネシン阻害剤 Download PDF

Info

Publication number
JP2006516140A
JP2006516140A JP2004563641A JP2004563641A JP2006516140A JP 2006516140 A JP2006516140 A JP 2006516140A JP 2004563641 A JP2004563641 A JP 2004563641A JP 2004563641 A JP2004563641 A JP 2004563641A JP 2006516140 A JP2006516140 A JP 2006516140A
Authority
JP
Japan
Prior art keywords
alkyl
alkylene
heterocyclyl
aryl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2004563641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006516140A5 (https=
Inventor
フラリー，マーク・イー
ガルバツチヨ，ロバート・エム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of JP2006516140A publication Critical patent/JP2006516140A/ja
Publication of JP2006516140A5 publication Critical patent/JP2006516140A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2004563641A 2002-12-20 2003-12-16 有糸分裂キネシン阻害剤 Ceased JP2006516140A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43510202P 2002-12-20 2002-12-20
PCT/US2003/040126 WO2004058148A2 (en) 2002-12-20 2003-12-16 Mitotic kinesin inhibitors

Publications (2)

Publication Number Publication Date
JP2006516140A true JP2006516140A (ja) 2006-06-22
JP2006516140A5 JP2006516140A5 (https=) 2010-07-15

Family

ID=32682157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004563641A Ceased JP2006516140A (ja) 2002-12-20 2003-12-16 有糸分裂キネシン阻害剤

Country Status (6)

Country Link
US (1) US7622468B2 (https=)
EP (1) EP1581497A4 (https=)
JP (1) JP2006516140A (https=)
AU (1) AU2003297230B2 (https=)
CA (1) CA2509212A1 (https=)
WO (1) WO2004058148A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003299672B2 (en) * 2002-12-20 2010-02-25 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2004109290A2 (en) * 2003-05-30 2004-12-16 Rosetta Inpharmatics Llc Methods for identifying modulators of kinesin activity
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
AR068888A1 (es) 2007-10-19 2009-12-16 Schering Corp Derivados de 1, 3, 4 - tiadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la quinesina ksp.
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN103804283B (zh) * 2012-11-06 2016-04-20 中国科学院大连化学物理研究所 一种制备1,2-二氢吡啶衍生物的方法
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CN104756984B (zh) * 2015-03-30 2016-08-17 上海应用技术学院 多取代顺式二苯乙烯类化合物作为农用杀菌剂的应用
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833669A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US12595248B2 (en) 2019-12-17 2026-04-07 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN115003303B (zh) 2019-12-17 2024-03-08 默沙东公司 Prmt5抑制剂
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
WO2026027944A1 (en) 2024-07-30 2026-02-05 Sairopa B.V. Anti-sirp alpha antibody formulations and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6422869A (en) * 1987-06-24 1989-01-25 Lundbeck & Co As H Heterocyclic compound
JPH01203380A (ja) * 1987-12-22 1989-08-16 Merck Sharp & Dohme Ltd メチルテトラヒドロピリジルオキサジアゾール類
JPH04235985A (ja) * 1990-05-31 1992-08-25 Merck Sharp & Dohme Ltd 緑内障の治療に使用するための置換オキサジアゾール類及びチアジアゾール類及びその用途を有する新規な化合物
JP2000119250A (ja) * 1998-08-11 2000-04-25 Takeda Chem Ind Ltd 環状アミド化合物、その製造法、中間体及び除草剤
JP2005536479A (ja) * 2002-06-14 2005-12-02 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
JP2006506456A (ja) * 2002-10-18 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
AU2003299672B2 (en) * 2002-12-20 2010-02-25 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6422869A (en) * 1987-06-24 1989-01-25 Lundbeck & Co As H Heterocyclic compound
JPH01203380A (ja) * 1987-12-22 1989-08-16 Merck Sharp & Dohme Ltd メチルテトラヒドロピリジルオキサジアゾール類
JPH04235985A (ja) * 1990-05-31 1992-08-25 Merck Sharp & Dohme Ltd 緑内障の治療に使用するための置換オキサジアゾール類及びチアジアゾール類及びその用途を有する新規な化合物
JP2000119250A (ja) * 1998-08-11 2000-04-25 Takeda Chem Ind Ltd 環状アミド化合物、その製造法、中間体及び除草剤
JP2005536479A (ja) * 2002-06-14 2005-12-02 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
JP2006506456A (ja) * 2002-10-18 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤

Also Published As

Publication number Publication date
WO2004058148A3 (en) 2004-09-16
AU2003297230B2 (en) 2009-11-26
US20060058327A1 (en) 2006-03-16
EP1581497A4 (en) 2009-03-18
US7622468B2 (en) 2009-11-24
CA2509212A1 (en) 2004-07-15
AU2003297230A1 (en) 2004-07-22
EP1581497A2 (en) 2005-10-05
WO2004058148A2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
JP4590270B2 (ja) 有糸分裂キネシン阻害剤
JP2006516140A (ja) 有糸分裂キネシン阻害剤
JP4391825B2 (ja) 有糸分裂キネシン阻害剤
JP4467979B2 (ja) 有糸分裂キネシン阻害剤
JP4463679B2 (ja) 有糸分裂キネシン阻害剤
JP4597519B2 (ja) 有糸分裂キネシン阻害薬
JP4399269B2 (ja) 有糸分裂性キネシン阻害薬
JP4377323B2 (ja) 有糸分裂キネシン阻害剤
CN100548296C (zh) 有丝分裂驱动蛋白抑制剂
JP2005511581A (ja) 有糸分裂キネシン阻害剤
JP2006506401A (ja) 有糸分裂キネシン阻害薬
JP2005515208A (ja) 有糸分裂性キネシン阻害剤
JP2005530806A (ja) 有糸分裂キネシン阻害薬
US7625912B2 (en) Mitotic kinesin inhibitors
JP2007517071A (ja) 有糸分裂キネシン阻害剤
JP2008535803A (ja) 有糸分裂キネシン阻害剤
JP2008524329A (ja) 有糸分裂キネシン阻害剤
JP2008530094A (ja) 有糸分裂キネシン阻害剤
CN100403900C (zh) 有丝分裂驱动蛋白抑制剂
JP2008505089A (ja) 有糸分裂キネシン阻害剤
CN1980938B (zh) 有丝分裂驱动蛋白抑制剂
JP2008505094A (ja) 有糸分裂キネシン阻害剤
US20070149553A1 (en) Mitotic kinesin inhibitors
JP2008510012A (ja) 有糸分裂キネシン阻害剤
JP2008533144A (ja) 有糸分裂キネシン阻害剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061109

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100531

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100531

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101102

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20110329